Publication details
Rituximab (MabTera)-nový biologický lék v terapii revmatoidní artritidy
| Title in English | Rituximab (MabThera - a new biological medicine in rheumatoid arthritis therapy |
|---|---|
| Authors | |
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Immunology |
| Keywords | rheumatoid arthritis rituximab therapie |
| Description | Rheumatoid arthritis (RA) is a serious, chronic, inflamatory disorder that damage the joint. At present we do not have any means of curing RA, the main objective for treatment is to induce remision of the disorder . Rituximab (MabThera) a monoklonal antibody against CD 20 posotove B-lymphocytes, is a new biological medicine approved for RA. It represents a new hope for patients with active RA, for whom earlier therapy with TNF alfa blpockers has failed |